Neuroscience & CNS
Part of Biotech - Drug Development
 BIIB | Biogen Inc. Common Stock | $32.5b | $252.03 | -0.3% | 352.1K |
 JAZZ | Jazz Pharmaceuticals, Inc. | $15.3b | $206.76 | +0.3% | 202.8K |
 NBIX | Neurocrine Biosciences Inc | $14.6b | $144.88 | -0.6% | 452.6K |
 AXSM | Axsome Therapeutics, Inc | $9.4b | $142.90 | -1.5% | 461.4K |
 CYTK | Cytokinetics Inc. | $9.1b | $60.94 | +0.1% | 391.3K |
 TGTX | TG Therapeutics, Inc. | $8.3b | $56.38 | +2.7% | 579.3K |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | $8.3b | $267.87 | -0.1% | 108.3K |
 ALKS | Alkermes Inc. plc | $7.0b | $44.60 | +0.3% | 439.0K |
 PTCT | PTC Therapeutics, Inc. | $5.3b | $61.48 | +0.2% | 526.1K |
 DFTX | Definium Therapeutics, Inc. Common Shares | $5.0b | $37.51 | +4.8% | 584.3K |
 INDV | Indivior Pharmaceuticals, Inc. Common Stock | $4.2b | $34.40 | -0.7% | 738.7K |
 XENE | Xenon Pharmaceuticals Inc | $3.7b | $35.89 | +0.4% | 430.4K |
 AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | $3.5b | $27.59 | +1.9% | 467.5K |
 ACAD | Acadia Pharmaceuticals Inc. | $3.4b | $20.13 | +1.9% | 566.7K |
 RGC | Regencell Bioscience Holdings Limited Ordinary Shares | $3.4b | $7.34 | +9.5% | 193.3K |
 DNLI | Denali Therapeutics Inc. Common Stock | $3.2b | $19.11 | +2.3% | 588.1K |
 ATAI | AtaiBeckley Inc. Common Stock | $2.7b | $7.33 | 0.0% | N/A |
 SUPN | Supernus Pharmaceuticals, Inc. | $2.5b | $40.53 | -1.0% | 487.1K |
 HRMY | Harmony Biosciences Holdings, Inc. Common Stock | $2.3b | $37.58 | +1.5% | 271.4K |
 BHVN | Biohaven Ltd. | $1.9b | $14.98 | +3.4% | 976.9K |
 STOK | Stoke Therapeutics, Inc. Common Stock | $1.7b | $26.14 | +2.4% | 522.2K |
 GHRS | GH Research PLC Ordinary Shares | $1.6b | $20.07 | +4.3% | 117.5K |
 RAPP | Rapport Therapeutics, Inc. Common Stock | $1.5b | $27.68 | +8.4% | 256.8K |
 TSHA | Taysha Gene Therapies, Inc. Common Stock | $1.5b | $4.13 | +2.6% | 1.2M |
 LBRX | LB Pharmaceuticals Inc Common Stock | $1.2b | $39.66 | +0.7% | 113.2K |
 ANRO | Alto Neuroscience Inc. | $1.0b | $22.92 | +3.3% | 165.6K |
 SPTX | Seaport Therapeutics, Inc. Common Stock | $1.0b | $21.68 | +3.5% | 63.5K |
 TBPH | Theravance Biopharma, Inc. | $0.9b | $17.05 | 0.0% | N/A |
 ALMS | Alumis Inc. Common Stock | $0.9b | $6.39 | -2.0% | 942.8K |
 HELP | Helus Pharma Inc. Common Stock | $0.9b | $10.53 | +1.0% | 925.3K |
 ANNX | Annexon, Inc. Common Stock | $0.8b | $3.75 | +1.2% | 1.0M |
 COLL | Collegium Pharmaceutical, Inc. Common Stock | $0.7b | $22.89 | -1.5% | 173.5K |
 AQST | Aquestive Therapeutics, Inc. Common Stock | $0.6b | $4.00 | +1.0% | 714.9K |
 MPLT | MapLight Therapeutics, Inc. Common Stock | $0.5b | $7.64 | +0.3% | 83.8K |
 DRUG | Bright Minds Biosciences Inc. Common Stock | $0.5b | $54.05 | +4.9% | 32.8K |
 CTNM | Contineum Therapeutics, Inc. Class A Common Stock | $493.6m | $8.87 | +8.1% | 264.9K |
 OVID | Ovid Therapeutics Inc. Common Stock | $464.8m | $2.23 | +3.2% | 566.6K |
 PRTA | Prothena Corporation plc Ordinary Shares | $429.2m | $8.66 | +2.7% | 150.3K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $384.0m | $3.29 | +1.5% | 466.4K |
 VNDA | Vanda Pharmaceuticals Inc. | $279.9m | $3.94 | 0.0% | 1.1M |
 IKT | Inhibikase Therapeutics, Inc. Common Stock | $279.1m | $1.54 | +1.6% | 716.2K |
 ACIU | AC Immune SA | $270.9m | $2.14 | -7.6% | 363.6K |
 ELDN | Eledon Pharmaceuticals, Inc. Common Stock | $202.3m | $2.33 | +5.4% | 318.4K |
 ALEC | Alector, Inc. Common Stock | $202.1m | $2.08 | +13.4% | 2.0M |
 ACOG | Alpha Cognition Inc. Common Stock | $198.2m | $8.83 | +6.1% | 107.4K |
 NGEN | NervGen Pharma Corp. Common stock | $191.4m | $1.52 | +7.7% | 267.2K |
 AVXL | Anavex Life Sciences | $168.7m | $1.26 | -1.6% | 628.6K |
 PEPG | PepGen Inc. Common Stock | $157.9m | $2.52 | +1.6% | 494.4K |
 NERV | Minerva Neurosciences, Inc | $156.6m | $2.25 | +1.1% | 93.1K |
 TNXP | Tonix Pharmaceuticals Holding Corp. | $152.8m | $5.38 | +0.4% | 475.9K |